newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSXV:ARCH, OTCQB:ACHFF) today announced that it has received central Institutional Review Board ("IRB") approval of the protocol and related